

Approved for  
8.0 AMA PRA Category 1 Credits™

PROUDLY HOSTED BY



10<sup>th</sup>  
ANNUAL



Spring To Life™

The graphic for the "Spring To Life" logo shows a green silhouette of a person jumping joyfully, surrounded by several red blood cells. The text "Spring To Life" is written in a large, purple, sans-serif font.

Conference on  
Aggressive Lymphomas 2023

*a CME-accredited, 2-day educational conference*

**May 5-6, 2023**

**Live In-Person @ The Saratoga Hilton, Saratoga Springs, NY**

Hosted By



Accredited by




Conference Collaborators



Organized By





# Spring To Life™

Dear Healthcare Professional Colleagues:

On behalf of New York Oncology Hematology, we welcome you to our **10th Annual Spring to Life Conference**. The focus this year is Aggressive Lymphomas 2023.

Lymphomas represent a diverse spectrum of diseases of varied biologic, clinical, prognostic, and therapeutic characteristics. We continue evolving our basic science understanding of cells of origin and gene expression, changing our classification and interpretation. Therapies are also continuing to evolve, impacting cures and meaningfully extended remissions, especially in harnessing our immune system as therapy. Yet many challenges remain.

We look forward to another robust agenda across this diverse spectrum of both B and T cell non-Hodgkin's lymphomas and our Keynote Address on Hodgkin's Lymphoma. This year we also are introducing a Benign Hematology special session, recognizing that complex hematology is anything but benign, with the equal need to update our understanding and management. This year we focus on Thrombotic Microangiopathies.

Spring to Life emphasizes the vital collaboration of community-based hematologists/oncologists with academic research and clinical leaders that advance our knowledge and mutual care of our patients. Our faculty of speakers brings in our rich regional academic expertise to join local specialists.


I want to thank Dr. Mihir Raval of NYOH for joining me as Co-Moderator this year and for his help in the conference organization, along with our organizing partners at myMedEd. An important thank you to our conference sponsors and exhibitors who make this event possible year after year. Please take some time to visit the Exhibitors as we collectively work together to improve the lives and outcomes of those living with malignant diseases.

Lastly, thank you for attending the **10th Annual Spring to Life: Conference on Aggressive Lymphomas 2023!** And enjoy as Saratoga also springs to life at this beautiful time of year in the northeast.

Sincerely,


Ira Zackon, MD  
Conference Planning Committee Co-Chair  
Past President  
New York Oncology Hematology

Mihir Raval, MD  
Conference Planning Committee Co-Chair  
New York Oncology Hematology



| Friday, May 5, 2023   |                                                                                                                                                                                                                                                                                   | FACULTY                                                                            |
|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|
| 10:00 AM - 12:00 PM   | <b>REGISTRATION / EXHIBITS / BREAKFAST</b>                                                                                                                                                                                                                                        |                                                                                    |
| 11:00 AM - 11:45 AM   | <b>OPTIONAL NON-CME ANCILLARY EVENT – BROADWAY 4</b><br>Topic: SARCLISA + Kd: An Anti-CD38 Combination for the Treatment of Multiple Myeloma Patients as Early as First Relapse<br>Presenter: Dr. Raymond Thertulien (Novant Health Weisiger Cancer Institute)<br>Sponsor: Sanofi |                                                                                    |
| 12:00 PM - 12:10 PM   | <b>Introduction</b>                                                                                                                                                                                                                                                               | Co-Chairs & Moderators<br>Dr. Ira Zackon (NYOH), Dr. Mihir Raval (NYOH)            |
| 12:10 PM - 12:40 PM   | <b>Evolving Pathology Classification of Lymphomas</b>                                                                                                                                                                                                                             | Dr. Tipu Nazeer (AMC)<br>Dr. Mahmoud Aldyab (AMC)                                  |
| 12:45 PM - 1:15 PM    | <b>Primary CNS Lymphoma</b>                                                                                                                                                                                                                                                       | Dr. Susan Weaver (NYOH)                                                            |
| 1:20 PM - 1:50 PM     | <b>Burkitt's Lymphoma</b>                                                                                                                                                                                                                                                         | Dr. Mihir Raval (NYOH)                                                             |
| 1:55 PM - 2:25 PM     | <b>EXHIBITOR BREAK / AFTERNOON SNACK</b>                                                                                                                                                                                                                                          |                                                                                    |
| 2:25 PM - 2:55 PM     | <b>Primary Mediastinal B Cell Lymphoma (PMBCL)</b>                                                                                                                                                                                                                                | Dr. Reju George (NYOH)                                                             |
| 3:00 PM - 3:30 PM     | <b>EBV Associated Lymphoproliferative Disease</b>                                                                                                                                                                                                                                 | Dr. Qin Zen (NYOH)                                                                 |
| 3:35 PM - 4:05 PM     | <b>Benign Hematology: Thrombotic Microangiopathies</b>                                                                                                                                                                                                                            | Dr. Jeffrey C Laurence (Cornell)                                                   |
| 4:05 PM - 4:15 PM     | <b>Concluding Remarks</b>                                                                                                                                                                                                                                                         | <b>Co-Chairs &amp; Moderators</b><br>Dr. Ira Zackon (NYOH), Dr. Mihir Raval (NYOH) |
| 4:15 PM - 5:10 PM     | <b>Networking</b> (Invited Faculty, Attendees, Exhibitors and Sponsors)                                                                                                                                                                                                           |                                                                                    |
| 5:10 PM - 5:55 PM     | <b>OPTIONAL NON-CME ANCILLARY EVENT – BROADWAY 4</b><br>Topic: A First In-class NME in 3L+ Follicular Lymphoma<br>Presenter: Dr. Kerstin Scheper (Robert Wood Johnson University Hospital)<br>Sponsor: Genentech                                                                  |                                                                                    |
| Saturday, May 6, 2023 |                                                                                                                                                                                                                                                                                   | FACULTY                                                                            |
| 7:00 AM - 8:00 AM     | <b>REGISTRATION / EXHIBITS / BREAKFAST</b>                                                                                                                                                                                                                                        |                                                                                    |
| 8:00 AM - 8:05 AM     | <b>Introduction</b>                                                                                                                                                                                                                                                               | <b>Co-Chairs &amp; Moderators</b><br>Dr. Ira Zackon (NYOH), Dr. Mihir Raval (NYOH) |
| 8:10 AM - 8:40 AM     | <b>DLBCL/Transformed Lymphoma</b>                                                                                                                                                                                                                                                 | Dr. Patrick Reagan (UOR)                                                           |
| 8:45 AM - 9:15 AM     | <b>Geriatric Assessment and Management in Hematologic Malignancies</b>                                                                                                                                                                                                            | Dr. Melissa (Kah Poh) Loh (UOR)                                                    |
| 9:20 AM - 9:50 AM     | <b>High-Grade B Cell Lymphomas</b>                                                                                                                                                                                                                                                | Dr. Reid Merryman (DFCI)                                                           |
| 9:55 AM - 10:10 AM    | <b>EXHIBITOR BREAK</b>                                                                                                                                                                                                                                                            |                                                                                    |
| 10:15 AM - 10:45 AM   | <b>T Cell Lymphomas</b>                                                                                                                                                                                                                                                           | Dr. Steven Horwitz (MSKCC)                                                         |
| 10:50 AM - 11:20 AM   | <b>Unusual Lymphomas</b>                                                                                                                                                                                                                                                          | Dr. Austin Kim (DFCI)                                                              |
| 11:25 AM - 11:55 AM   | <b>Emerging Therapeutics in the Evolving Clinico-Genomic Lymphoma Landscapes</b>                                                                                                                                                                                                  | Dr. Jennifer Crombie (DF)                                                          |





|                            |                                                                                                                                                                                                              |                                                                                    |
|----------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|
| <b>12:00 PM - 1:00 PM</b>  | <b>Lunch and EXHIBITOR Break</b>                                                                                                                                                                             |                                                                                    |
| <b>12:00 PM – 12:45 PM</b> | <b>OPTIONAL NON-CME ANCILLARY EVENT – BROADWAY 4</b><br>Topic: CAR T-Cell Therapy and the Crucial Role of the Primary Oncology Team<br>Presenter: Dr. Iris Isufi (Yale Cancer Center)<br>Sponsor: Kite Pharm |                                                                                    |
| <b>1:05 PM - 2:05 PM</b>   | <b>Keynote Address: Hodgkin’s Lymphoma</b>                                                                                                                                                                   | Dr. Alison Moskowitz (MSKCC)                                                       |
| <b>2:10 PM - 2:40 PM</b>   | <b>Scenarios of Relapsed/Refractory Disease: A Panel Discussion</b>                                                                                                                                          |                                                                                    |
| <b>2:45 PM - 2:55 PM</b>   | <b>Concluding Remarks</b>                                                                                                                                                                                    | <b>Co-Chairs &amp; Moderators</b><br>Dr. Ira Zackon (NYOH), Dr. Mihir Raval (NYOH) |
| <b>2:55 PM - 4:00 PM</b>   | <b>Networking</b> (Invited Faculty, Attendees, Exhibitors and Sponsors)                                                                                                                                      |                                                                                    |
| <b>3:30 PM – 5:30 PM</b>   | <b>10th Annual Spring to Life Community Event: Enduring Big Emotions</b> (High Rock Room)<br>(All Faculty, Attendees, and Exhibitors from the Spring to Life Conference are welcome to attend)               |                                                                                    |

### PROGRAM DESCRIPTION

The 10th Annual Spring to Life Conference is developed with the Medical Society of the State of New York, New York Oncology Hematology, the Leukemia Lymphoma Society, the American Cancer Society, and myMedEd, Inc. The focus this year is Aggressive Lymphomas. The conference will be in person at The Saratoga Hilton in Saratoga Springs, NY.

### EDUCATIONAL GOAL

This conference aims to educate practitioners and update their knowledge of the biological pathways, diagnosis, and current guidelines, as well as the existing and emerging therapies for managing patients with Lymphoma.

### TARGET AUDIENCE

The target audience for this conference is medical oncologists, hematologists, pathologists, oncology nurses, advanced practice providers, family practitioners, primary care practitioners, allied health professionals, and other providers interested in the care of patients with Lymphoma.

### LEARNING OBJECTIVES

After participating in this activity, learners will be better able to:

- Understand the current classification system of the lymphoma
- Discuss updated data on novel agents and therapeutic approaches for patients with aggressive lymphoma.
- Discuss current standard of care approach in patient with newly diagnosed and relapsed refractory aggressive B cell lymphoma and T cell lymphoma.
- Understand the diagnostic and management approaches in patient with uncommon presentation of lymphoma and CNS lymphoma
- Understand the disease process and treatment strategies in patients with Hodgkin Lymphoma.
- Identify the unmet need and upcoming strategies in elderly patients with lymphoma.
- Understand the complex diagnosis paradigm and management of thrombotic microangiopathies

## ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Society of the State of New York (MSSNY) and myMedEd, Inc. MSSNY is accredited by the ACCME to provide continuing medical education for physicians.



## CREDIT DESIGNATION STATEMENT

The Medical Society of the State of New York designates this live activity for a maximum of 8.0 *AMA PRA Category 1 Credits*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses and other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for *AMA PRA Category 1 Credit*<sup>™</sup> from organizations accredited by the ACCME, please consult your professional licensing board.

As an ACCME-accredited provider, MSSNY will identify and mitigate relevant financial relationships of all individuals who control CME content.

## ASSURANCE OF BALANCED, UNBIASED, AND FAIR CONTENT

As an ACCME-accredited provider, MSSNY must identify and mitigate relevant financial relationships of all individuals controlling CME content.

Financial relationships are relevant if the following three conditions are met for the prospective person who will control the content of the education:

- A financial relationship, in any amount, exists between the person in control of content and an ineligible company.

- The financial relationship existed during the past 24 months.
- The educational content is related to the products of an ineligible company with whom the person has a financial relationship.

Mechanisms to ensure that presentations are free from commercial bias are in place. Faculty will also disclose any off-label and/or investigational use of pharmaceuticals or instruments discussed in their presentation.

## PLANNER DISCLOSURES

Nicole Falco: Nothing to disclose.

Charles Gonzalez, MD, Chair, MSSNY Subcommittee on Educational Program Reviewer: Nothing to disclose.

## HOW TO CLAIM CREDIT


- Check in at the registration desk for each day of participation.
- You will be emailed instructions for completing a program evaluation, claiming credit and printing your certificate within 7 days.

## SLIDE DOWNLOADS

Slides will be available within 7 days after the conference. An email will be sent once they are available for download. Not all presentations will be available due to reprints and permission restrictions.

## CONFERENCE RECORDINGS

Within 30 days, the conference recording will be available for viewing. An email will be sent when the recording is available. The recording is not going to be accredited for continuing education credits.



## PLANNING COMMITTEE AND CO-CHAIRS/MODERATORS

---



**Ira Zackon, MD**

New York Oncology Hematology,  
Immediate Past President  
Hematologist/Medical Oncologist  
NYOH Albany Medical Center  
Clinical Assistant Professor  
Albany Medical College  
Albany, NY



**Mihir Raval, MD, MPH**

Hematology and Stem cell transplant  
New York Oncology and Hematology,  
Clinical Assistant Professor  
Transfusion Committee Chair  
Albany Medical College  
Albany, NY

## FACULTY

---



**Mahmoud Aldyab, MD**

Pathology Residency  
Albany Medical Center  
Albany, NY



**Jennifer Crombie, MD**

Assistant Professor of  
Medicine  
Dana-Farber Cancer Institute  
Boston, MA



**Reju George, MD**

Hematologist-Oncologist  
New York Oncology  
Hematology  
Albany, NY



**Steven Horwitz, MD**

Medical Oncologist  
Member and Attending  
Physician  
Memorial Sloan Kettering  
Cancer Center  
New York, NY






**Austin Kim, MD**

Instructor of Medicine  
Harvard Medical School  
Dana-Farber Cancer Institute  
Boston, MA




**Jeffrey Laurence, MD**

Professor of Medicine  
Weill Cornell Medicine  
New York, NY



**Kah Poh (Melissa) Loh, MBBCh  
BAO, MS**

Assistant Professor  
University of Rochester Medical  
Center  
Rochester, NY




**Reid W. Merryman, MD**

Assistant Professor  
Dana-Farber Cancer Institute  
Boston, MA



**Alison Moskowitz, MD**

Associate Attending  
Memorial Sloan Kettering Cancer  
Center  
New York, NY



**Tipu Nazeer, MD**

Professor and Program Director  
Director, Hematopathology  
Albany Medical Center  
Albany, NY




**Patrick Reagan, MD**

Associate Professor  
Wilmut Cancer Institute  
Rochester, NY




**Susan Weaver, MD**

Assistant Professor  
Albany Medical Center  
New York Oncology Hematology  
Albany, NY



**Qin Zen, MD, PhD**

Attending Physician  
New York Oncology Hematology  
Albany, NY



## BIOGRAPHIES

---



**Mahmoud Aldyab, MD** is a graduate of Damascus University. He started his residency in pathology (AP/CP) in 2018 at Albany Medical Center. He received his board certification from the American Board of Pathology in 2022. He is currently doing a fellowship in hematopathology at Albany Medical Center.

DISCLOSURES: Nothing to disclose.



**Jennifer Crombie, MD** received her undergraduate degree from Dartmouth College and her medical degree from the University of Massachusetts. She completed her residency training in internal medicine at Brigham and Women's Hospital and fellowship training in hematology and oncology at Dana-Farber/Partners CancerCare.

DISCLOSURES: Consultant: Kite Pharma, Genmab, ADC Therapeutics, MorphSys, Incyte. Research Funding: Genentech, Merck, Bayer, AbbVie.



**Dr. Reju M. George** is a hematologist at New York Oncology and Hematology (NYOH) in Albany, New York, specializing in hematological malignancies. He earned his medical degree at St George's University School of Medicine, Grenada. He completed an Internal Medicine residency and then a Medical Oncology and Hematology fellowship at Baystate Medical Center in Springfield, Massachusetts.

DISCLOSURES: Nothing to disclose.





**Dr. Steven Horwitz** is an Attending Physician in the Department of Medicine at Memorial Hospital for Cancer and Allied Diseases and a Member of Memorial Sloan Kettering Cancer Center in New York City. He earned his medical degree at Case Western Reserve University School of Medicine, completed an internship and residency in internal medicine at the University of Rochester/Strong Memorial Hospital, and then completed a fellowship in medical oncology at Stanford University Medical Center.

Much of his current research is dedicated to investigating targeted or immunotherapeutic approaches to identify better and often less toxic treatments for individuals with T-cell lymphomas. His research also focuses on better understanding mechanisms of response and resistance to novel drugs in T-cell lymphoma to help provide individualized treatments in the future.

Dr. Horwitz participates in several national and international committees and consortiums dedicated to understanding and advancing treatment for T-cell lymphoma. Since 2017 he has been the Chair of the NCCN panel on Guidelines for the Treatment of T-Cell/Primary Cutaneous B-Cell Lymphomas.

**DISCLOSURES:** Consultant: Auxilius Pharma, Abcuro, Inc., Cimieo Therapeutics, Daiichi Sankyo, Kyowa Hakko Kirin, ONO Pharmaceuticals, SecuraBio, Shoreline Biosciences, Inc., Takeda, Trillium Therapeutics, Tubulis, Yingli Pharma Limited. Research support: ADC Therapeutics, Affimed, Celgene, CRISPR Therapeutics, Daiichi Sankyo, Kyowa Hakko Kirin, Millennium/Takeda, Seagen, Trillium Therapeutics, Verastem/SecuraBio





**Austin Kim, MD** received his medical degree from Dartmouth Medical School in 2010. He completed postgraduate training in internal medicine in 2013 and a fellowship in medical oncology and hematology in 2017, both at the University of Massachusetts Medical School. For one year between internal medicine residency and fellowship, he was on staff as a physician in the Division of Hospital Medicine at Mount Auburn Hospital in Cambridge, Massachusetts. He joined the division of hematologic malignancies at Dana-Farber in 2017.

**DISCLOSURES:** Nothing to disclose.



**Jeffrey Laurence, MD** is a Professor of Medicine in the Division of Hematology-Oncology, an Attending Physician at New York Presbyterian Hospital, and Director of the Laboratory for AIDS Virus Research and co-director of the Comprehensive Hemophilia Center at those institutions. He is also Senior Scientific Consultant for Programs at amfAR, The Foundation for AIDS Research, and Editor-in-Chief of two medical journals: AIDS Patient Care and STDs (in its 37th year) and Translational Research (formerly the Journal of Laboratory and Clinical Medicine, in its 108th year). He graduated with a BA summa cum laude from Columbia University, an MD with honors from the University of Chicago Pritzker School of Medicine, and was elected a Rhodes Scholar to Oxford University. He has authored over 160 original articles predominantly related to HIV pathogenesis or the thrombotic microangiopathies.

**DISCLOSURES:** Grant Recipient: Omeros Corporation, Alexion, Jazz Pharmaceuticals.




**Kah Poh Loh, MBCh BAO, MS** is a geriatric hematologist and oncologist specializing in caring for older adults with hematologic malignancies. Dr. Loh leads all geriatric hematology clinical efforts at her institution, including building a de novo geriatric hematology consultative clinic, inspiring and helping to organize geriatric hematology clinical trials, and training local and international mentees.

Dr. Loh's research focuses on developing and implementing behavioral and supportive care interventions, mainly digital health technologies, on improving outcomes for older adults with blood cancer. These interventions include a patient-centered communication tool to facilitate shared decision-making, a mobile health exercise intervention to reduce functional decline during cancer treatments, and a serious illness communication intervention delivered via telehealth to facilitate goal-concordant care. She is supported by a National Cancer Institute (NCI) K99/R00, the National Institute of Aging (NIA) R03 GEMSSTAR Award, the American Society of Clinical Oncology Conquer Cancer Foundation Career Development Award, and the Wilmot Cancer Institute Research Fellowship Award. She has published over 140 peer-reviewed articles, presented over 130 oral and poster presentations, and received >30 research and travel awards.

Nationally, Dr. Loh was a member of the ASCO Annual Meeting Education Committee for Geriatric Oncology (Chair 2020-2021) and the American Geriatrics Society (AGS) Cancer and Aging Special Interest Group (Chair 2021-2022). She is a member of the Junior Investigator Board and Junior Faculty Lead in the Analytics Core for the NIA-funded Cancer and Aging Research (CARG) R21/R33 infrastructure grant, a member of the American Society of Hematology Committee on Education Affairs, a Board member of the International Society of Geriatric Oncology (SIOG), and member of the AGS Research Committee as well as the Methods, Annual Meeting, and NIA subcommittees.

Dr. Loh has mentored over 20 trainees and faculty both locally and internationally. She has served or currently serves on four Ph.D. dissertation committees (Epidemiology, Biostatistics, and Nursing) and a Master capstone project (Biostatistics).


DISCLOSURES: Honoraria: Pfizer



**Reid W. Merryman, MD**, is an Assistant Professor of Medicine at Harvard Medical School, Boston, MA, USA, and an attending physician in the Division of Lymphoma at Dana-Farber Cancer Institute (DFCI). He received his undergraduate degree from the University of Notre Dame and his medical degree from Harvard Medical School. He completed residency training in internal medicine at Brigham and Women's Hospital and fellowship training in hematology and oncology at Dana-Farber/Partners Cancer Care. His research interests include 1) the development of novel immune-based treatments in Hodgkin lymphoma and indolent non-Hodgkin lymphoma and 2) identifying novel biomarkers (like circulating tumor DNA) to guide response-adapted treatment approaches.

DISCLOSURES: Advisory Board: Genmab, Adaptive Biotechnology, BMS, AbbVie, Intellia, Epizyme. Institutional Research Funding: Genmab, Merck, Genentech/Roche, BMS. Consultant: AlphaSights.





**Dr. Alison Moskowitz** received her MD from the Albert Einstein College of Medicine and completed residency in Internal Medicine at Columbia University Medical Center. She trained in Hematology/Oncology at Memorial Sloan Kettering Cancer Center (MSKCC) in New York, where she joined the faculty in 2010 as Assistant Attending on the Lymphoma Service. Dr. Moskowitz focuses her clinical practice and research on developing new agents and treatment strategies for patients with T-cell lymphoma and Hodgkin lymphoma. She is the principal investigator and co-principal investigator of multiple clinical trials evaluating targeted agents and new combinations in T-cell lymphoma and Hodgkin lymphoma.

**DISCLOSURES:** Consultant: ADC Therapeutics, Affimed, Bio Ascend, Imbrium Therapeutics L.P./Perdue, Janpix Ltd, Merck, Seagen, Tessa Therapeutics, Takeda. Research Support: ADC Therapeutics, Beigene, Miragen, Seagen, Merck, Bristol-Myers Squibb, Incyte, SecuraBio.



**Tipu Nazeer, MD's** areas of interest include hematopathology and urologic pathology. He has been studying large cell lymphomas with a special emphasis on cell cycle pathways and potential targets for therapeutic intervention. Dr. Nazeer is a professor at Albany Medical College.

Dr. Nazeer is an active member of the upstate hematology group promoting research and education. He has authored 67 articles in peer-reviewed journals and multiple textbook chapters. Dr. Nazeer has been involved in developing an international society of urologic pathology (ISUP) grading, Vancouver classification, and diagnostic and prognostic markers of renal tumors.

**DISCLOSURES:** Nothing to disclose.





**Dr. Mihir Raval** is a Clinical Assistant Professor of Hematology/Oncology at Albany Medical College in New York and an attending Hematology and Stem cell transplant physician at New York Oncology and Hematology. He earned his medical degree from Smt. N.H.L. Municipal Medical College in Ahmedabad, India, completed a Master of Public Health at the West Chester University of Pennsylvania. He completed his Internal Medicine residency at the University of North Dakota and worked as a Chief Resident. Subsequently, he spent 3 years as a Clinical Assistant Professor and Hospitalist at the University of North Dakota, at Essential Health, in Fargo, ND. Later, he joined fellowship training in Hematology and Oncology at the University of Arkansas in Little Rock and became a Chief Fellow. Dr. Raval is board certified in Internal Medicine, Hematology and Oncology.

Dr. Raval's clinical and research interests include hematological malignancy and stem cell transplantation. He is Principal Investigator in industry-sponsored clinical trials and has published research in abstracts and original articles in peer-reviewed journals.

Dr. Raval is an active member of the American Society of Clinical Oncology and the American Society of Hematology. In his spare time, he likes to go for a run or a hike and spend time with his wife, dog, and cat.

**DISCLOSURES:** Advisor: Agios Pharmaceuticals, Jazz Pharmaceuticals, Karyopharm Therapeutics, Symbiotix. Advisor and Speaker: Adaptive Biotechnology, ADCT Therapeutics, AstraZeneca Pharma, Bristol Myers Squibb Pharmaceuticals, Glaxo Smith Klein Pharmaceuticals, Takeda Pharmaceuticals. Associated Research Funding: Amgen Biotechnologies, AstraZeneca Biopharmaceuticals, Genentech Biotechnologies, Janssen Pharmaceuticals, Merk Sharp and Dohme, Seagen. Speaker: AbbVie Pharmaceuticals, Alexion Biopharma, Astellas Pharmaceuticals, Beigene Biopharma, CTI Biopharma, Epizyme Biopharma, Incyte/Morphosys Pharmaceuticals, Sanofi Genzyme.





**Patrick Reagan, MD** is an Associate Professor of Medicine at the Wilmot Cancer Institute.

Dr. Reagan received his medical degree from Upstate Medical University in Syracuse, NY. He completed his internship and residency at the University of Virginia. He then served as a chief resident at the University of Virginia. He completed his fellowship in hematology at the Wilmot Cancer Institute at the University of Rochester Medical Center.

He started his faculty appointment at the Wilmot Cancer Institute in July 2015.

DISCLOSURES: Consultant: Kite Pharma, Caribou Biosciences. Research Funding: Genentech, Seagen.




**Susan Weaver, MD** is an Assistant Professor of Neurology at Albany Medical Center, having graduated from Albany Medical College where she also pursued her internship and residency in Neurology prior to completing fellowship training in Neuro-oncology at Memorial Sloan-Kettering Cancer Center. She has been practicing Neuro-oncology at Albany Medical Center and New York Oncology/Hematology for over 20 years. Her primary focus is the evaluation and treatment of adult malignant glioma, primary CNS lymphoma and complications of cancer in the nervous system.

DISCLOSURES: Nothing to disclose.



**Ira Zackon, MD**, is a Hematologist/ Oncologist, former Stem Cell Transplant Program Director, and immediate past President of New York Oncology Hematology, PC (NYOH). He is an Assistant Clinical Professor at Albany Medical College in Albany, New York. After earning a medical degree in 1986 from McGill University in Montreal, Canada, he completed an internship and residency in Internal Medicine at Royal Victoria Hospital in Montreal in 1989. Dr. Zackon completed Hematology/Medical Oncology fellowships at Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire (1990-1992), and Northwestern University Medical Center, Chicago, Illinois (1992-1994). At NYOH, Dr. Zackon has further developed the practice's autologous stem cell transplant program, expanded collaborative care for allogeneic bone marrow transplant patients at NYOH with regional transplant centers, and focused NYOH participation in research trials in the hematologic malignancies through the US Oncology Network and the Blood Cancer Research Partnership in association with the Dana-Farber Cancer Institute in Boston, Massachusetts. He continues to practice with NYOH and is a part-time Senior Medical Director for Real-World Data Research with Ontada.

DISCLOSURES: Consultant: Epizyme



**Dr. Qin Zen, MD**, is a hematology & oncology specialist in Albany, NY. He is affiliated with medical facilities such as Saint Peter's Hospital and Albany Medical Center Hospital.

DISCLOSURES: Nothing to disclose.



The Healthcare Professional sessions at the  
**10TH Annual Spring to Life Conference: Focus on Aggressive Lymphomas**

is supported by an educational grant from:

**Seagen**

**Thank you to our Product Theater Sponsors:**

05/05/23 – 11:00am – 11:45am

Optional Non-Cme Ancillary Event – Broadway 4

**Topic: SARCLISA + Kd: An Anti-CD38 Combination for the Treatment of Multiple Myeloma Patients as Early as First Relapse**

is provided by: **Sanofi**

05/05/23 – 5:10pm – 5:55pm

Optional Non-Cme Ancillary Event – Broadway 4

**Topic: A First In-class NME in 3L+ Follicular Lymphoma**

is provided by: **Genentech**

05/06/23 - 12:00 pm – 12:45 pm

Optional Non-Cme Ancillary Event – Broadway 4

**Topic: CAR T-Cell Therapy and the Crucial Role of the Primary Oncology Team**

is provided by: **Kite Pharma**

Thank you to the following exhibitors for supporting the  
Healthcare Professional sessions at the

**10TH Annual Spring to Life Conference: Focus on Aggressive Lymphomas**

**PLATINUM SPONSORSHIP**

CTI BioPharma  
Seagen Inc

**GOLD SPONSORSHIP**

Adaptive Biotechnologies  
ADC Therapeutics  
Agiros  
Apellis Pharmaceuticals  
AstraZeneca  
Bristol Myers Squibb  
Daiichi Sankyo, Inc.  
Exelixis  
Genentech  
Incyte Corporation  
Kite Pharma  
Kyowa Kirin  
Novartis Hematology  
Pfizer, Inc.  
Pharmacosmos Therapeutics  
Sanofi  
Servier Pharmaceuticals  
Takeda Oncology

**SILVER SPONSORSHIP**

Beigene

**BRONZE SPONSORSHIP**

Abbvie  
Alexion Pharmaceuticals  
Astellas  
Blueprint Medicines  
Ipsen Biopharmaceuticals  
Janssen Biotech, Inc.  
Jazz Pharmaceuticals  
Karyopharm Therapeutics  
Merck & Co.  
MorphoSys  
NeoGenomics  
Pharmacyclics, an Abbvie Company





# NYOH Community Cancer Foundation

Helping local families cope with the cost of cancer.

Cancer treatment takes a toll. Not just on the body, but on a family's bottom line.



By paying for rent and household bills or providing gift cards to purchase gas and groceries, we help people with cancer focus on their treatment, instead of worrying about daily household stressors.



**DONATE TODAY!**  
[nyohfoundation.org](http://nyohfoundation.org)



The NYOH Community Cancer Foundation is recognized as a tax-exempt organization under section 501(c)(3) of the Internal Revenue Code, EIN 14-1822194.



# Cancer is **one chapter** in your story.

If you or a loved one find yourself with a cancer diagnosis, the experts at New York Oncology Hematology are here to help you continue your story. Contact us today to schedule an appointment or a second opinion.

Visit [newyorkoncology.com](http://newyorkoncology.com) to learn more.

Albany • Albany Med • Amsterdam • Clifton Park • Hudson • Troy

**NYOH**  
New York  
Oncology  
Hematology







# Spring To Life™

## CONFERENCE COLLABORATORS

---

**American Cancer Society**  
**Leukemia Lymphoma Society**  
**New York Oncology Hematology**

*Hosted By*

---



*Accredited by*

---



*Conference Collaborators*

---



*Organized By*

---

